MEI Pharma Investor Presentation - February 2018 - Richmond Club

Watch the fully interactive Talk-Deck version of this presentation at onlineinvestmentconference.co...
MEI Pharma Inc. - Developing therapies for cancer
Symbol: MEIP (NASDAQ)
Presenter: Dr. Dan Gold, President & CEO
Occasion: Richmond Club Lunch, Toronto February 26, 2018
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective, oral PI3K delta inhibitor, voruciclib, an oral, selective CDK inhibitor, and ME-344, a novel mitochondrial inhibitor.
Head Office:
MEI Pharma, Inc.
3611 Valley Centre Drive, Suite 500
San Diego, CA 92130
Tel: [phone]
W: www.meipharma.com